Cerebrolysin
Also known as: FPF-1070, Brain-derived peptide preparation
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
Cerebrolysin is a porcine brain-derived peptide preparation containing a mixture of low-molecular-weight neuropeptides and free amino acids obtained by standardized enzymatic proteolysis of lipid-free porcine brain proteins. It is approved in over 40 countries (including Austria, Germany, Russia, China, and South Korea) for the treatment of stroke, traumatic brain injury, and dementia, but it is not FDA-approved and is not available by prescription in the United States. Multiple randomized controlled trials have been conducted, though the overall quality of evidence is debated, with some Cochrane reviews noting methodological concerns.
Plain Language Summary
Cerebrolysin is a mixture of brain-protective peptides derived from pig brain tissue. It is approved in many countries in Europe and Asia for treating stroke, brain injuries, and dementia, but it is not approved in the United States. Several clinical trials have shown modest benefits for brain recovery, but the quality of these studies has been questioned. In the US, it is only available through grey-market channels.
Mechanism of Action
Cerebrolysin contains a standardized mixture of neurotrophic peptides that mimic the activity of endogenous neurotrophic factors including BDNF, GDNF, NGF, and CNTF. The peptide mixture crosses the blood-brain barrier and exerts pleiotropic neuroprotective effects including: inhibition of calpain-mediated neuronal death, reduction of amyloid-beta aggregation, modulation of GSK-3beta activity (reducing tau hyperphosphorylation), promotion of neurogenesis and synaptogenesis, and enhancement of neuronal sprouting. The multi-target mechanism is thought to provide broader neuroprotection than single-molecule approaches.
Evidence Summary
Multiple RCTs have evaluated cerebrolysin in acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer disease. A meta-analysis by Bornstein et al. (2018) showed modest improvement in early neurological outcomes in stroke. Guekht et al. (2011) demonstrated improvement on ADAS-cog in vascular dementia. However, Cochrane systematic reviews have noted significant methodological limitations including inadequate blinding, industry sponsorship, and inconsistent outcome measures across trials. A large trial (CASTA) in acute stroke did not meet its primary endpoint. The evidence is sufficient for regulatory approval in some jurisdictions but falls below Western regulatory standards.
Safety Profile
Cerebrolysin has been generally well tolerated in clinical trials. The most common adverse events are dizziness, headache, and injection site reactions. Rare cases of agitation and insomnia have been reported. As a porcine-derived biological product, there is a theoretical risk of allergic reactions or prion disease, though no such cases have been documented. The safety profile is considered favorable relative to its pharmacological class.
Contraindications
- Known hypersensitivity to cerebrolysin or porcine-derived products
- Severe renal impairment (limited clearance data)
- Status epilepticus (may lower seizure threshold)
- Pregnancy and breastfeeding (insufficient safety data)
Adverse Events
- Dizziness
- Headache
- Injection site reactions
- Nausea
- Agitation or restlessness (uncommon)
- Insomnia (uncommon)
- Hypersensitivity reactions (rare)
Interactions
- No formal drug interaction studies of high quality
- Caution with MAO inhibitors (theoretical serotonergic interaction)
- Caution with antiepileptic drugs (may alter seizure threshold)
Regulatory Notes
Cerebrolysin is approved in over 40 countries for neurological indications but is not FDA-approved. It has never completed a successful FDA pivotal trial. In the US, it is considered an unapproved drug and is available only through grey-market importation. Manufactured by EVER Neuro Pharma (Austria) under GMP conditions for approved markets.
Monitoring Considerations
Standard neurological assessment tools (NIHSS for stroke, ADAS-cog for dementia). Monitor for allergic reactions during initial infusions. Renal function should be assessed in elderly patients. No specific laboratory monitoring required based on available data.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Manufactured product: amber glass ampoules or vials. Store at room temperature (not exceeding 25 degrees C). Protect from light. Do not freeze. For IV infusion, dilute in 0.9% saline or Ringer solution. Reconstituted solutions should be used within 24 hours. Grey-market products may not maintain these standards.
References
- 1meta-analysis
Cerebrolysin for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Bornstein NM, Guekht A, Vester J, et al. (2018). Drugs
Key findings: Meta-analysis of RCTs showed improved early neurological outcomes with cerebrolysin adjunctive therapy in acute ischemic stroke patients. Effect sizes were modest but statistically significant.
Limitations: Heterogeneous trial designs. Several studies had methodological limitations. Not blinded in some trials.
View source - 2RCT
Cerebrolysin in Vascular Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
Guekht AB, Moessler H, Novak PH, et al. (2011). Journal of the Neurological Sciences
Key findings: Cerebrolysin showed statistically significant improvement on ADAS-cog and CIBIC+ in patients with mild to moderate vascular dementia at 24 weeks.
Limitations: Single trial. Moderate sample size. Funded by manufacturer (EVER Neuro Pharma).
View source - 3review
Cerebrolysin: A Review of Its Use in Dementia
Chen CC, Wei ST, Tsaia SC, et al. (2013). Drugs & Aging
Key findings: Review of cerebrolysin pharmacology and clinical data across multiple neurological indications. Summarizes neurotrophic mechanism and safety profile from controlled trials.
Limitations: Narrative review. Notes regulatory inconsistencies across countries.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Cognitive
Semax
ACTH(4-7)-Pro-Gly-Pro · Semax 1%
Semax is a lab-made peptide based on a fragment of a natural brain hormone (ACTH). It was developed in Russia, where it is an approved medication for brain protection after stroke and for cognitive enhancement. It is given as a nasal spray. In Western countries it is not approved but is available in the grey market as a nootropic (brain-boosting) peptide.
Selank
TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro
Selank is a lab-made peptide based on a natural immune peptide called tuftsin, developed in Russia where it is approved for anxiety and cognitive support. It is given as a nasal spray and is notable for reducing anxiety without causing drowsiness or sedation. It is not approved in Western countries but is available in the grey market.
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · Norleual
Dihexa is a research peptide that was developed to improve brain function by boosting a growth factor pathway involved in forming new brain connections. In animal studies, it improved memory and learning at remarkably low doses. It has never been tested in humans, and its safety in people is completely unknown. It is available only through grey-market sources without any quality assurance.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider